临床中的干细胞疗法。

Stem cell therapies in the clinic.

作者信息

Acharya Shrinivas, Shaha Suyog, Bibbey Michael Griffith, Mukherji Malini, Zhao Zongmin, Mitragotri Samir

机构信息

John A. Paulson School of Engineering and Applied Sciences Harvard University Massachusetts USA.

Wyss Institute for Biologically Inspired Engineering Harvard University Boston Massachusetts USA.

出版信息

Bioeng Transl Med. 2025 Feb 4;10(3):e70000. doi: 10.1002/btm2.70000. eCollection 2025 May.

Abstract

Stem cell therapies have emerged as a transformative approach in modern medicine, with the potential to address and possibly cure a broad spectrum of diseases. These therapies utilize living stem cells that can perform complex biological functions not replicable by traditional drugs. Stem cell therapies have an expanding therapeutic landscape, with several products already approved and numerous clinical trials underway. Among the various stem cell types, hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are most widely studied. In this review, we provide a detailed analysis of the current clinical landscape of stem cell therapies. We review 27 stem cell products that have received regulatory approvals and discuss 800 ongoing clinical trials, with a focus on HSCs and MSCs. We also discuss the critical challenges to be addressed to facilitate the clinical translation of stem cell therapies.

摘要

干细胞疗法已成为现代医学中一种变革性的方法,具有解决并可能治愈多种疾病的潜力。这些疗法利用活的干细胞,其能够执行传统药物无法复制的复杂生物学功能。干细胞疗法的治疗领域正在不断扩大,已有数种产品获批,并且有大量临床试验正在进行。在各种干细胞类型中,造血干细胞(HSCs)和间充质干细胞(MSCs)的研究最为广泛。在本综述中,我们对干细胞疗法的当前临床情况进行了详细分析。我们回顾了27种已获得监管批准的干细胞产品,并讨论了800项正在进行的临床试验,重点关注造血干细胞和间充质干细胞。我们还讨论了为促进干细胞疗法的临床转化需要解决的关键挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc40/12079495/0789089a0317/BTM2-10-e70000-g008.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索